Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference
Reata Pharmaceuticals (NASDAQ: RETA) has announced management's participation in investor meetings during the Citi 17th Annual BioPharma Conference on September 7-8, 2022, in Boston, Massachusetts. The company focuses on developing novel therapeutics for severe diseases by targeting key molecular pathways related to metabolism and inflammation. Their primary clinical candidates, omaveloxolone and bardoxolone methyl, are investigational drugs aimed at reducing oxidative stress. However, their safety and efficacy remain unverified by regulatory agencies.
- Participation in a major investor conference could enhance visibility and attract potential investors.
- Focus on developing novel therapeutics for serious diseases demonstrates commitment to innovation.
- Safety and efficacy of key investigational drugs, omaveloxolone and bardoxolone, remain unproven.
- Forward-looking statements highlight inherent risks in product development and regulatory approvals.
About Reata
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, omaveloxolone and bardoxolone methyl (“bardoxolone”), target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Omaveloxolone and bardoxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop, and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reata’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005756/en/
(972) 865-2219
https://www.reatapharma.com/
Investor Relations & Media Relations:
https://www.reatapharma.com/contact-us/
Source:
FAQ
What is Reata Pharmaceuticals' stock symbol?
When is the Citi 17th Annual BioPharma Conference?
What are Reata's main investigational drugs?
Where will the Citi BioPharma Conference be held?
What is the focus of Reata Pharmaceuticals?
